Alpha Teknova (TKNO) investor relations material

Executive summary

• Achieved record Q2 2026 revenue of $12.2 million, up 18–18.5% year-over-year, with growth across nearly all end markets and both Lab Essentials and Clinical Solutions segments contributing equally.

• Gross margin improved to 40.1% from 38.7% in Q2 2025, reflecting operational efficiencies.

• Net loss for Q2 2026 was $3.2 million (or -$0.06/share), improved from $3.6 million (-$0.07/share) in Q2 2025.

• Launched Build-Tek, an AI-powered custom order configurator, to accelerate custom product sales and enhance customer engagement.

• Raised full-year 2026 revenue guidance to $45–$47 million, with commercial investments and improved biotech funding expected to drive further growth.

Financial highlights

• Q2 2026 revenue: $12.2M, up 18–18.5% year-over-year; Lab Essentials: $9.2M (up 18%), Clinical Solutions: $2.4M (up 18%).

• Gross profit: $4.9M (up from $4.0M); gross margin: 40.1% (up from 38.7%).

• Adjusted EBITDA: -$0.7M (improved from -$0.8M); free cash outflow: $0.6M (down from $2.3M).

• Cash, equivalents, and short-term investments: $17.4M as of June 30, 2026; total borrowings: $13.2M.

• Operating expenses: $7.8M (up from $7.4M), mainly due to sales and marketing investments.

Outlook and guidance

• 2026 revenue guidance raised to $45–$47M, with 14% growth at midpoint.

• Free cash outflow for 2026 expected to be less than $8M.

• Adjusted EBITDA positive expected at $52–$57M annualized revenue; positive quarter possible before end of 2027.

• Gross margin expected in mid-to-upper 30s percentage for 2026.

• Operating expenses forecasted at least $8M per quarter through 2026.